<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534935</url>
  </required_header>
  <id_info>
    <org_study_id>B1971035</org_study_id>
    <secondary_id>2011-004400-38</secondary_id>
    <nct_id>NCT02534935</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.</brief_title>
  <official_title>A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To &lt;18 Months Or 18 To &lt;24 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the immunogenicity, safety and tolerability of a
      new vaccine that might prevent meningococcal B disease. The study will be conducted in
      healthy toddlers aged between 12 and 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Anticipated">February 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects achieving an hSBA titer ≥ LLOQ 1 month after the third vaccination, for each of the 4 primary MnB test strains in healthy toddlers aged 12 to &lt;18 months at study entry.</measure>
    <time_frame>Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects achieving an hSBA titer ≥ LLOQ 1 month after the third vaccination, for each of the 4 primary MnB test strains in healthy toddlers aged 18 to &lt;24 months at study entry.</measure>
    <time_frame>Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</measure>
    <time_frame>Month 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</measure>
    <time_frame>Month 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with at least 1 SAE 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the active SAE collection period.</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with at least 1 medically attended adverse event 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the AE collection period.</measure>
    <time_frame>Up to 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with at least 1 newly diagnosed chronic medical condition 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the AE collection period.</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with at least 1 adverse event 30 days after each vaccination, 30 days after any vaccination and during the vaccination phase.</measure>
    <time_frame>Up to 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</measure>
    <time_frame>Month 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</measure>
    <time_frame>Month 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hSBA titers ≥ LLOQ for each of the 4 primary MnB test strains 1 month after the third vaccination with bivalent rLP2086 in subjects 12 to &lt;24 months.</measure>
    <time_frame>Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hSBA titers ≥ LLOQ for each of the 4 primary MnB test strains at 1 month after the second vaccination with bivalent rLP2086 and 6, 12, 24, 36, and 48 months after the third vaccination with bivalent rLP2086.</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with hSBA titers ≥ LLOQ, ≥1:4, ≥1:8, ≥1:16, ≥1:32, ≥ 1:64, and ≥ 1:128 for each of the 4 primary MnB strains at each applicable blood sampling visit.</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for each of the 4 primary test strains at each applicable blood sampling visit.</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Meningococcal B Disease</condition>
  <arm_group>
    <arm_group_label>rLP2086 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm stratified by age:
≥12 to &lt;18 months and ≥18 to &lt;24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm stratified by age:
≥12 to &lt;18 months and ≥18 to &lt;24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine</intervention_name>
    <description>60 mcg or 120mcg at 0, 2 and 6 months</description>
    <arm_group_label>rLP2086 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediatric HAV vaccine</intervention_name>
    <description>0.5-mL dose at months 0 and 6. Normal saline at month 2.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 12 to &lt;15 months or 18 to &lt;24 months during
             sentinel-cohort enrollment, Or,12 to &lt;24 months during expanded-cohort enrollment.

          -  Subjects must have received all vaccinations in the relevant National Immunization
             Program (NIP) for their age group.

          -  Subject is determined to be in good health by medical history, physical examination,
             and judgment of the investigator.

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine
             during Stage 1 of the study.

          -  Contraindication to vaccination with any HAV vaccine or known latex allergy.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  A known or suspected disorder of the immune system that would prevent an immune
             response to the vaccine, such as subjects with congenital or acquired defects in
             B-cell function or those receiving systemic immunosuppressive therapy. Subjects with
             terminal complement deficiency may be included.

          -  History of microbiologically proven disease caused by N meningitidis or Neisseria
             gonorrhoeae.

          -  Significant neurologic disorder or history of seizure (excluding simple febrile
             seizure).

          -  Receipt of any blood products, including immunoglobulin, within 6 months before the
             first study vaccination until the end of Stage 1.

          -  Current chronic use of systemic antibiotics.

          -  Received any investigational drugs, vaccines or devices within 28 days before
             administration of the first study vaccination and/or during study participation.

          -  Any neuroinflammatory or autoimmune condition, including but not limited to
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Australian Clinical Research Network</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's And Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Telethon Kids Institute</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Canberra Hospital, Paediatric Research and Clinical Trials</name>
      <address>
        <city>Canberra, Garran</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VIRGo c/- Melbourne School of Population and Global Health</name>
      <address>
        <city>Victoria</city>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordinace Praktickeho Lekare Pro Deti A Dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MEDICENTRUM 6 s.r.o. - Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prakticky Lekar Pro Deti A Mladez</name>
      <address>
        <city>Tynec Nad Sazavou</city>
        <zip>257 41</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitamed Galaj i Cichomski sp.j.</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski dr n. med. Jerzy Brzostek</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Hanna Czajka</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Gravita</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;NZOZ Praktyka Lekarza Rodzinnego &quot;&quot;Eskulap&quot;&quot; sp. z o.o.&quot;</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Lecznictwa Ambulatoryjnego &quot;Michalkowice&quot; Jarosz i Partnerzy Spolka Lekarska</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy, Oddzial Pediatryczny z pododdzialem niemowlecym</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Pediatrii i Chorob Infekcyjnych</name>
      <address>
        <city>Worclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971035&amp;StudyName=Immunogenicity%2C%20Safety%20and%20Tolerability%20of%20Meningococcal%20B%20Vaccine%20in%20Healthy%20Toddlers.%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>February 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2 Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability Study</keyword>
  <keyword>rLP2086 Vaccine</keyword>
  <keyword>Healthy Toddlers</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Duration of Immunogenicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
